Miricorilant in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 1b Results Highlight Intermittent Dosing Strategy
This phase 1b study of miricorilant, a selective glucocorticoid receptor modulator, shows significant reductions in liver fat and improvements in liver health markers in patients with presumed metabolic dysfunction-associated steatohepatitis, particularly with intermittent dosing.
